Search Results - "DE FRAIPONT, F"

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network by Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., de Crémoux, P., Solassol, J., de Fraipont, F., Bièche, I., Cayre, A., Favre-Guillevin, E., Tomasini, P., Wislez, M., Besse, B., Legrain, M., Voegeli, A.-C., Baudrin, L., Morin, F., Zalcman, G., Quoix, E., Blons, H., Cadranel, J.

“…There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. EGFR…”
Get full text

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial by Moro-Sibilot, D., Cozic, N., Pérol, M., Mazières, J., Otto, J., Souquet, P.J., Bahleda, R., Wislez, M., Zalcman, G., Guibert, S.D., Barlési, F., Mennecier, B., Monnet, I., Sabatier, R., Bota, S., Dubos, C., Verriele, V., Haddad, V., Ferretti, G., Cortot, A., De Fraipont, F., Jimenez, M., Hoog-Labouret, N., Vassal, G.

“…In 2013, the French National Cancer Institute initiated the AcSé program to provide patients with secure access to targeted therapies outside of their marketed…”
Get full text

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project by Blons, H., Oudart, J.-B., Merlio, J.-P., Debieuvre, D., de Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P.‐P., Fraboulet-Moreau, S., Ouafik, L., Moro-Sibilot, D., Lemoine, A., Langlais, A, Missy, P., Morin, F., Souquet, P.-J., Barlesi, F., Cadranel, J., Beau‐Faller, M.

“…•Response to EGFR TKI is heterogeneous among patients with EGFR mutated NSCLC.•Routine use of NGS enables co-mutations detection that may impact response to…”
Get full text

Early detection of lung cancer: role of biomarkers by Brambilla, C, Fievet, F, Jeanmart, M, de Fraipont, F, Lantuejoul, S, Frappat, V, Ferretti, G, Brichon, P.Y, Moro-Sibilot, D

“…Early detection of lung cancer requires none or few invasive techniques. Distal lung cancer (40% of the cases in most European countries) can be sensitively…”
Get full text

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial by Moro-Sibilot, D, Cozic, N, Pérol, M, Mazières, J, Otto, J, Souquet, P J, Bahleda, R, Wislez, M, Zalcman, G, Guibert, S D, Barlési, F, Mennecier, B, Monnet, I, Sabatier, R, Bota, S, Dubos, C, Verriele, V, Haddad, V, Ferretti, G, Cortot, A, De Fraipont, F, Jimenez, M, Hoog-Labouret, N, Vassal, G

“…In 2013, the French National Cancer Institute initiated the AcSé program to provide patients with secure access to targeted therapies outside of their marketed…”
Get full text

Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study by Blons, H., Oudart, J.-B., Merlio, J.-P., Hominal, S., de Fraipont, F., Debieuvre, D., Escande, F., Audigier Valette, C., Bringuier, P.-P., Moreau Fraboulet, S., Ouafik, L., Moro-Sibilot, D., Lemoine, A., Langlais, A., Missy, P., Morin, F., Souquet, P.-J., Barlesi, F., Cadranel, J., Beau-Faller, M.

Get full text

Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe by Hofman, P., Calabrese, F., Kern, I., Adam, J., Alarcão, A., Alborelli, I., Anton, N.T., Arndt, A., Avdalyan, A., Barberis, M., Bégueret, H., Bisig, B., Blons, H., Boström, P., Brcic, L., Bubanovic, G., Buisson, A., Caliò, A., Cannone, M., Carvalho, L., Caumont, C., Cayre, A., Chalabreysse, L., Chenard, M.P., Conde, E., Copin, M.C., Côté, J.F., D’Haene, N., Dai, H.Y., de Leval, L., Delongova, P., Denčić-Fekete, M., Fabre, A., Ferenc, F., Forest, F., de Fraipont, F., Garcia-Martos, M., Gauchotte, G., Geraghty, R., Guerin, E., Guerrero, D., Hernandez, S., Hurník, P., Jean-Jacques, B., Kashofer, K., Kazdal, D., Lantuejoul, S., Leonce, C., Lupo, A., Malapelle, U., Matej, R., Merlin, J.L., Mertz, K.D., Morel, A., Mutka, A., Normanno, N., Ovidiu, P., Panizo, A., Papotti, M.G., Parobkova, E., Pasello, G., Pauwels, P., Pelosi, G., Penault-Llorca, F., Picot, T., Piton, N., Pittaro, A., Planchard, G., Poté, N., Radonic, T., Rapa, I., Rappa, A., Roma, C., Rot, M., Sabourin, J.C., Salmon, I., Prince, S. Savic, Scarpa, A., Schuuring, E., Serre, I., Siozopoulou, V., Sizaret, D., Smojver-Ježek, S., Solassol, J., Steinestel, K., Stojšić, J., Syrykh, C., Timofeev, S., Troncone, G., Uguen, A., Valmary-Degano, S., Vigier, A., Volante, M., Wahl, S.G.F., Stenzinger, A., Ilié, M.

“…Testing for epidermal growth factor receptor (EGFR) mutations is an essential recommendation in guidelines for metastatic non-squamous non-small-cell lung…”
Get full text

Cell cycle arrest is sufficient for p53-mediated tumor regression by DUBREZ, L, COLL, J-L, HURBIN, A, DE FRAIPONT, F, LANTEJOUL, S, FAVROT, M-C

“…p53 gene therapy can induce tumor regression, but the low efficacy of in vivo gene transfer has greatly hampered the mechanistic analysis of this antitumoral…”
Get full text

Parietal operculum and motor cortex activities predict motor recovery in moderate to severe stroke by Hannanu, Firdaus Fabrice, Zeffiro, Thomas A, Lamalle, Laurent, Heck, Olivier, Renard, Félix, Thuriot, Antoine, Krainik, Alexandre, Hommel, Marc, Detante, Olivier, Jaillard, Assia

“…While motor recovery following mild stroke has been extensively studied with neuroimaging, mechanisms of recovery after moderate to severe strokes of the types…”
Get full text

Mechanisms of resistance to anti-BRAF treatments by Charles, J, Martel, C, de Fraipont, F, Leccia, M-T, Robert, C, Busser, B

“…In patients with melanoma positive for the BRAF V600 mutation, clinical response to specific BRAF inhibitors is usually rapid and striking, with significant…”
Get full text

Promoter methylation of genes in bronchial lavages: A marker for early diagnosis of primary and relapsing non-small cell lung cancer? by de Fraipont, F., Moro-Sibilot, D., Michelland, S., Brambilla, E., Brambilla, C., Favrot, M.C.

“…A prospective screening program, including CT, autofluorescent bronchoscopy, biopsies and bronchial lavage (BL) collection, was initiated with the specific…”
Get full text

Paracrine Control of the Adult Adrenal Cortex Vasculature by Vascular Endothelial Growth Factor by Vittet, D., Ciais, D., Keramidas, M., Fraipont, F. De, Feige, J. J.

“…The extensive vascular network that irrigates the adult adrenal cortex is essential for both the delivery of oxygen and nutrients to glandular steroidogenic…”
Get full text

Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors : Correlation with genotypic alterations by DE FRAIPONT, F, EL ATIFI, M, GICQUEL, C, BERTAGNA, X, CHAMBAZ, E. M, FEIGE, J. J

“…Several studies have supported the hypothesis that adrenocortical tumor formation is the result of a multistep process. The angiogenic switch has been proposed…”
Get full text

Contribution of molecular biology to new diagnostic and/or prognostic markers characterization in cancerogenesis by de Fraipont, F

“…During malignant transformation, cells accumulate genetic and epigenetic alterations. Since ten years, the knowledge of the whole human genome, associated with…”
Get more information

Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial by Jaillard, Assia, Hommel, Marc, Moisan, Anaick, Zeffiro, Thomas A., Favre-Wiki, Isabelle M., Barbieux-Guillot, Marianne, Vadot, Wilfried, Marcel, Sebastien, Lamalle, Laurent, Grand, Sylvie, Detante, Olivier

“…While preclinical stroke studies have shown that mesenchymal stem cells (MSCs) promote recovery, few randomized controlled trials (RCT) have assessed cell…”
Get full text

Mécanismes de résistance aux inhibiteurs de BRAF by Charles, J., Martel, C., de Fraipont, F., Leccia, M.-T., Robert, C., Busser, B.

“…Environ un mélanome sur deux présente une mutation sur le codon 600 du gène BRAF. Les patients dont la tumeur est mutée V600 ont une réponse aux traitements…”
Get full text

TRANSCRIPTION PROFILING OF BENIGN AND MALIGNANT ADRENAL TUMORS BY cDNA MACRO-ARRAY ANALYSIS by De Fraipont, F., Le Moigne, G., Defaye, G., El Atifi, M., Berger, F., Houlgatte, R., Gicquel, C., Plouin, P.-F., Bertagna, X., Chabre, O., Feige, J. J.

Get full text

Human Bone Marrow Mesenchymal Stem Cells Can Express Insulin and Key Transcription Factors of the Endocrine Pancreas Developmental Pathway upon Genetic and/or Microenvironmental Manipulation In Vitro by Moriscot, Christine, de Fraipont, Florence, Richard, Marie‐Jeanne, Marchand, Mélanie, Savatier, Pierre, Bosco, Domenico, Favrot, Marie, Benhamou, Pierre‐Yves

“…Multipotential stem cells can be selected from the bone marrow by plastic adhesion, expanded, and cultured. They are able to differentiate not only into…”
Get full text

ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer by Mc Leer, A., Duruisseaux, M., Pinsolle, J., Dubourg, S., Mondet, J., Phillips-Houlbracq, M., Magnat, N., Fauré, J., Chatagnon, A., de Fraipont, F., Giaj Levra, M., Toffart, A.C., Ferretti, G., Brambilla, E., Hainaut, P., Moro-Sibilot, D., Lantuéjoul, S.

Get full text

125PMolecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study by Blons, H, Oudart, J-B, Merlio, J-P, Hominal, S, de Fraipont, F, Debieuvre, D, Escande, F, Audigier Valette, C, Bringuier, P-P, Moreau Fraboulet, S, Ouafik, L, Moro-Sibilot, D, Lemoine, A, Langlais, A, Missy, P, Morin, F, Souquet, P-J, Barlesi, F, Cadranel, J, Beau-Faller, M

Get full text